DuPont de Nemours DD
DuPont de Nemours is a diversified chemical company that produces materials and solutions for electronics, water, mobility, and protection, selling to industrial and consumer sectors. DuPont shows solid financial health (ND/EBITDA 0.91) and exceptional earnings growth (149.6%), although its ROE is low (1.79%) and the dividend payout exceeds 100%, limiting its appeal to income investors.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
DuPont de Nemours is a diversified chemical company that produces materials and solutions for electronics, water, mobility, and protection, selling to industrial and consumer sectors. DuPont shows solid financial health (ND/EBITDA 0.91) and exceptional earnings growth (149.6%), although its ROE is low (1.79%) and the dividend payout exceeds 100%, limiting its appeal to income investors.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.7 |
| Quality / Moat | 4.7 |
| Valuation | 5.1 |
| Growth | 7.5 |
| Dividend | 2.2 |
| Momentum | 8.4 |
| Risk & Context | 5.4 |
OVERALL SCORE: 5.7/10
Context and risks
DuPont has exposure to PFAS (per- and polyfluoroalkyl substances) litigation, a material regulatory and legal risk in the chemical sector. Chemours' $455 million settlement suggests PFAS liabilities remain active and could affect DuPont.
News considered in the analysis
- Did Chemours' (CC) US$455 Million PFAS Deal Just Reframe Its Long‑Term Liability Narrative? — El acuerdo de Chemours sobre PFAS podría sentar precedente y afectar la exposición de DuPont a litigios similares, aunque la probabilidad de impacto directo es incierta.
- DuPont Expands Tyvek Portfolio With Lower-Carbon Material Innovation — Innovación de producto que refuerza la oferta sostenible de DuPont, con impacto moderado en crecimiento y reputación.
- Here's Why You Should Hold DuPont Stock in Your Portfolio for Now — Opinión genérica de analista sin información nueva.
- Qnity Is Added to the PHLX Semiconductor Index. Why the Stock Is Down. — Noticia sobre otra empresa del sector, sin impacto directo en DuPont.
- ‘The Age of Cures’ Review: What the Pharmacist Ordered — Reseña de libro sin relevancia para DuPont.
Verdict: Hold DuPont in portfolio: fundamentals are decent, but PFAS litigation risk and unsustainable payout warrant caution.
Main risk: The main risk is exposure to PFAS litigation, which could generate material liabilities and affect the company's valuation.
Other Basic Materials companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →